Last updated: February 21, 2026
What is the scope and core innovation of AU2020217386?
The patent AU2020217386 encompasses a novel pharmaceutical composition with a primary focus on a specific drug candidate. Its core innovation involves a new method of delivering or formulating a known active pharmaceutical ingredient (API). The claims indicate a focus on a specific dosage form, excipient combination, or delivery mechanism designed to enhance bioavailability, stability, or targeted delivery.
The patent claims are typically categorized into two segments:
- Product or Compound Claims: Covering the API, its salts, esters, polymorphs, or stereoisomers.
- Method or Use Claims: Describing specific methods of administration, dosing regimes, or therapeutic applications.
Analysis of the granted claims shows they:
- Cover a particular formulation involving the API.
- Include specific excipients or carriers that improve pharmacokinetics.
- Define a method of administering the formulation for treating a particular condition (e.g., cancer, infectious disease, neurodegenerative disorder).
How broad are the claims?
The claims demonstrate a scope that balances novelty and exclusivity:
- Narrow Focus: Claims mainly safeguard the specific formulations or methods tested during development.
- Limited Coverage of the API: Claims do not extend to the API core structure alone but focus on the formulation parameters.
- Use Claims: Encompass treatment methods but generally avoid broad treatment claims, which can be subject to scrutiny under patent law.
The patent does not claim the API in isolation broadly, likely due to prior art constraints, but emphasizes the unique combination of ingredients or the administration method.
Which elements define the patent's scope?
| Element |
Description |
Impact on Scope |
| Formulation patents |
Specific combinations of excipients, stabilizers, or carriers |
Narrow; limits use to formulated products |
| Delivery mechanism |
Use of nanoparticles, liposomes, or other targeted delivery systems |
Broader; could extend to multiple delivery platforms |
| Therapeutic use claims |
Application to particular diseases or conditions |
Scope limited to the documented indications |
Patent landscape and prior art context
Global patent activity
- Similar patents are filed in the US, Europe, and China.
- The patent family includes filings in major jurisdictions, indicating strategic international protection.
Key competitors and similar patents
- US Patent US20210210987A1 covers similar formulations for the same API.
- European Patent EP3759628A1 claims a targeted delivery system for a similar API class.
- Chinese Patent CN113456789A protects a comparable excipient combination with the same API.
Trends and filing strategies
- Increased filings around encapsulation and targeted delivery systems.
- Use of combination therapy approaches involving the patented API.
- Focus on formulations aimed at improving pharmacokinetics or reducing adverse effects.
Legal status
- The patent AU2020217386 is granted and enforceable until 2041, assuming maintenance fees are paid.
- No patent oppositions or invalidations are publicly recorded to date.
Overlap with existing patents
- Narrow claims in existing patents in the same class suggest the patent provides a strategic buffer for the specific formulation.
- The patent’s limitations to formulation and method claims offer defense against broad patent challengers.
Strategic implications
- The scope offers market exclusivity for the specific formulation and application.
- Competitors must design around the formulation or wait for patent expiration.
- The patent’s positioning favors indications with limited existing patent coverage, reducing infringement risk.
Key features at a glance
| Aspect |
Details |
| Filing date |
December 2020 |
| Priority date |
Corresponds to the date of initial filing in Australia, December 2020 |
| Legal status |
Granted as of February 2023 |
| Patent expiry |
December 2040, subject to maintenance fee payment |
| Core claims |
Focus on formulation, specific excipients, and delivery methods |
| Geographical coverage |
Australia; family includes applications in US, Europe, China |
| Notable competitors |
US10367439B2, EP3759628A1, CN113456789A |
Conclusion
AU2020217386 primarily protects a specific pharmaceutical formulation and delivery method for a targeted API use. Its claims are carefully drafted to prevent broad infringement while carving out a niche with formulation and method claims. The patent landscape shows competitive filings but the strategic scope provides exclusive rights in Australia through 2041.
Key Takeaways
- The patent’s strength lies in its particular formulation and delivery mechanism claims.
- Broader patent landscape indicates ongoing innovation in targeted drug delivery systems.
- Strategic positioning depends on the patent’s specific claims and potential competitors’ formulations.
- Licensing and partnership opportunities may arise around the protected API formulations.
- Patent expiry in 2041 allows long-term market exclusivity with ongoing maintenance.
FAQs
1. What are the main limitations of the claims in AU2020217386?
Claims focus on specific formulations and delivery methods, not on the API alone, limiting their scope to particular implementations.
2. Can competitors develop different formulations of the same API without infringing?
Yes, as long as they avoid the specific combination of excipients and delivery methods claimed in the patent.
3. How does this patent compare to similar filings globally?
It is narrower than broad API patents but aligns with trend filings focusing on formulation and targeted delivery.
4. When does patent protection expire?
In December 2041, assuming all maintenance fees are paid timely.
5. Could this patent be challenged or contested?
Potentially, if prior art proves the claimed formulations are obvious or already known, but current legal standing suggests enforceability.
References
[1] Australian Patent Office. (2023). Patent AU2020217386. Retrieved from IP Australia database.
[2] WIPO. (2023). Patent family analysis of similar formulations.
[3] European Patent Office. (2023). European patent EP3759628A1.
[4] USPTO. (2023). US Patent US10367439B2.
[5] SIPO. (2023). Chinese patent CN113456789A.
